HOME
SEARCH
RSS FEED
SUBSCRIBE
Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines
Case ID:
TAB-470
Web Published:
12/6/2022
Description:
Although flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. The present invention is directed toward vector stage replication-defective flaviviruses that are replication-defective in mosquito vectors that transmit them to humans. The replication-defective flaviviruses of the present invention demonstrate a limited ability to replicate in the vector organisms that transmit flaviviruses from one host to another. More specifically, the present invention is directed toward the construction and propagation of flaviviruses that possess 3'-noncoding regions altered in such a way as to prevent or severely limit viral reproduction in a vector organism. Not only is the dengue 1 mutant replication defective in mosquitoes, but it is also attenuated and immunogenic in monkeys. Moreover, it protects against challenge, thus it has strong potential as a dengue vaccine.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Attenuated_Host-Range_Restricted_Den gue_Viruses_Derived_by_Site-Directed_Mutagenesis_of_the_Conserved_3-Stem_and _Loop_Structure_in_Genomic_RNA_for_Use_as_Vaccines
Category(s):
Licensing
Vaccines
Infectious Disease
Bookmark this page
Download as PDF
For Information, Contact:
William Ronnenberg
Alternate TDC - FDA Special Volunteer
NIH Technology Transfer
240-402-4561
wronnenberg@mail.nih.gov
Inventors:
Lingling Zeng
Lewis Markoff
Keywords:
DC5BXX
DC5XXX
DCXXXX
Dengue (Flaviviridae)
DXXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum